55.13
                                            
                                Panoramica
                                Notizia
                                Cronologia dei prezzi
                                    Catena di opzioni
                                Financials
                                    Perché SUPN Giù?
                                Forum
                                Previsione
                        
                        Precedente Chiudi:
              $56.50
            Aprire:
              $56.33
            Volume 24 ore:
                904.19K
            Relative Volume:
              1.08
            Capitalizzazione di mercato:
                $3.09B
            Reddito:
              $665.13M
            Utile/perdita netta:
              $64.50M
            Rapporto P/E:
              48.18
            EPS:
                1.1442
            Flusso di cassa netto:
                $185.87M
            1 W Prestazione:
              +4.35%
            1M Prestazione:
              +15.36%
            6M Prestazione:
                +69.74%
            1 anno Prestazione:
              +61.81%
            Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
                  
                      Supernus Pharmaceuticals Inc
                    
                Settore
                  Telefono
                  
                      301-838-2500
                    
                Indirizzo
                  
                      9715 KEY WEST AVENUE, ROCKVILLE, MD
                    
                Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                SUPN
                            
                             Supernus Pharmaceuticals Inc | 55.13 | 3.17B | 665.13M | 64.50M | 185.87M | 1.1442 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione | 
|---|---|---|---|
| 2025-10-09 | Aggiornamento | Piper Sandler | Neutral → Overweight | 
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight | 
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | 
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight | 
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral | 
| 2023-01-03 | Ripresa | Jefferies | Buy | 
| 2021-12-01 | Ripresa | Jefferies | Buy | 
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy | 
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight | 
| 2020-06-15 | Ripresa | Jefferies | Hold | 
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold | 
| 2019-11-07 | Downgrade | Stifel | Buy → Hold | 
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold | 
| 2018-11-12 | Reiterato | B. Riley FBR | Buy | 
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy | 
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy | 
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy | 
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy | 
| 2017-10-19 | Iniziato | FBR & Co. | Buy | 
| 2017-09-19 | Downgrade | Stifel | Buy → Hold | 
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral | 
| 2017-07-14 | Iniziato | Janney | Neutral | 
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight | 
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform | 
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral | 
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy | 
| 2015-11-05 | Reiterato | Northland Capital | Outperform | 
| 2015-10-28 | Iniziato | Northland Capital | Outperform | 
                    Mostra tutto
                     
                  
                Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Supernus a new buy at BofA on 'underappreciated' CNS assets - MSN
Supernus Pharmaceuticals Inc. stock trendline breakdownWeekly Stock Report & Momentum Based Trading Ideas - newser.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.2025 Price Momentum & Verified Swing Trading Watchlists - newser.com
Can Supernus Pharmaceuticals Inc. stock continue upward trendDollar Strength & Fast Entry High Yield Stock Tips - newser.com
Top chart patterns to watch in Supernus Pharmaceuticals Inc.2025 Market Trends & High Accuracy Buy Signal Tips - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsEarnings Risk Report & Safe Swing Trade Setup Alerts - newser.com
Why Supernus Pharmaceuticals Inc. stock remains undervaluedBond Market & AI Forecasted Entry and Exit Points - newser.com
Sentiment analysis tools applied to Supernus Pharmaceuticals Inc.Market Growth Summary & Fast Gain Swing Trade Alerts - newser.com
Supernus Pharmaceuticals Hits New 52-Week High of $55.95 - Markets Mojo
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com
What institutional flow reveals about Supernus Pharmaceuticals Inc.Treasury Yields & Community Verified Trade Alerts - newser.com
Supernus Pharmaceuticals Inc Stock Analysis and ForecastQuarterly Earnings Review & Rapid Portfolio Appreciation - earlytimes.in
Supernus Pharmaceuticals (SUPN) Gains Market Attention with Key CNS Drugs - GuruFocus
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy - sharewise.com
Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? - Yahoo Finance
Supernus Pharmaceuticals Hits New 52-Week High of $53.28 - Markets Mojo
BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target - MarketScreener
B of A Securities Initiates Coverage on SUPN with a Buy Rating | - GuruFocus
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - Nasdaq
B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - Nasdaq
Is Supernus Pharmaceuticals Inc. stock near bottom after decline2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementTrade Analysis Summary & Safe Entry Trade Reports - newser.com
It’s Clear How Big Money Flows Lift Supernus - Yahoo Finance
Will Supernus Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Selloffs & Safe Entry Point Alerts - Fundação Cultural do Pará
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline - sharewise.com
Is Supernus Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Investment Summary & Smart Swing Trading Alerts - Fundação Cultural do Pará
Is Supernus Pharmaceuticals Inc. stock attractive after correctionEntry Point & Low Drawdown Trading Strategies - newser.com
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - sharewise.com
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale | 
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO | Oct 09 '25 | Sale | 50.57 | 59,900 | 3,029,336 | 1,206,578 | 
| NEWHALL CHARLES W III | Director | Oct 09 '25 | Sale | 50.77 | 25,000 | 1,269,234 | 104,644 | 
        Apri su Yahoo
        |
        Apri su Google
            |
            Aperto in Finviz
        |
        Apri in MarketWatch
            |
            Aperto a EDGAR    
        |
        Aperto su Reuters
    
    
                Capitalizzazione:
                 
                  | 
                Volume (24 ore):
                 
            
         
                     
                             Scarica l'app Stockscreener
                    Scarica l'app Stockscreener